Inflammatory bowel disease and lupus: a systematic review of the literature (Q38002687)

26 August 2017

Inflammatory bowel disease and lupus: a systematic review of the literature (English)

1 reference

inflammatory bowel diseases

26 August 2017

0 references

1 reference

Konstantinos H Katsanos

series ordinal

1

1 reference

PubMed ID

22504032

26 August 2017

Paraskevi V Voulgari

series ordinal

2

1 reference

PubMed ID

22504032

26 August 2017

Epameinondas V Tsianos

series ordinal

3

1 reference

26 August 2017

14 April 2012

1 reference

Journal of Crohn's and Colitis

26 August 2017

1 reference

26 August 2017

6

1 reference

26 August 2017

7

1 reference

26 August 2017

735-742

1 reference

GI vasculitis associated with systemic lupus erythematosus

26 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2012.03.005

Gastrointestinal involvement in systemic lupus erythematosus: insight into pathogenesis, diagnosis and treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2012.03.005

Gastrointestinal and hepatic manifestations of systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2012.03.005

A review of gastrointestinal manifestations of systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2012.03.005

The role of inflammatory bowel disease susceptibility loci in multiple sclerosis and systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2012.03.005

Lupus nephritis improvement after anti-tumor necrosis factor alpha monoclonal antibody (infliximab) treatment for Crohn's disease: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2012.03.005

Subacute cutaneous lupus erythematosus in a patient with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2012.03.005

Antiphospholipid syndrome manifested by ischemic stroke in a patient with Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2012.03.005

Salazosulfapyridine-induced lupus erythematosus syndrome in ulcerative colitis (author's transl)

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2012.03.005

Sulfasalazine-induced lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2012.03.005

Mesalazine induced lupus-like syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2012.03.005

Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2012.03.005

Lupus-like syndrome caused by 5-aminosalicylic acid in patients with inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2012.03.005

Predisposing factors in sulphasalazine-induced systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2012.03.005

Tumour necrosis factor alpha in systemic lupus erythematosus and anti-DNA autoantibody production

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2012.03.005

Autoantibody profile during short-term infliximab treatment for Crohn's disease: a prospective cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2012.03.005

American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2012.03.005

Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2012.03.005

A lupus-like syndrome associated with infliximab therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2012.03.005

Antibody responses in Crohn’s disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2012.03.005

The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2012.03.005

Adalimumab safety in global clinical trials of patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2012.03.005

Infliximab-induced lupus in Crohn's disease: a case report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2012.03.005

Skin reaction to adalimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2012.03.005

Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2012.03.005

Drug-induced lupus due to anti-tumor necrosis factor alpha agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2012.03.005

Efficacy and safety of adalimumab for the treatment of Crohn's disease in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2012.03.005

Characterization of patients with infliximab-induced lupus erythematosus and outcomes after retreatment with a second anti-TNF agent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2012.03.005

10.1016/J.CROHNS.2012.03.005

21 January 2018

Identifiers

DOI

1 reference

26 August 2017

1 reference

PubMed ID

22504032